P2, N=160, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

P2, N=50, Active, not recruiting, Universität des Saarlandes | Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> Jan 2027 | Trial primary completion date: Sep 2025 --> Jan 2026

P2, N=30, Not yet recruiting, Fudan University

These models have the potential to guide clinicians' treatment decisions and provide prognostic evaluations. Future prospective studies with larger cohorts, as well as integration of imaging biomarkers are warranted to optimize these predictive models.

Subsequently, multiple hepatic metastases and pelvic dissemination developed, and conventional chemotherapy including bevacizumab was ineffective...Switching to sorafenib led to further progression, but reintroduction of LVB reduced Tg levels...The patient has survived seven years since recurrence, including six years on LVB. The tumor behaved similarly to poorly differentiated thyroid carcinoma, with Tg levels reflecting disease activity and LVB demonstrating the potential for long-term tumor control.

Although conversion therapy can significantly downstage advanced hepatocellular carcinoma and allow curative-intent resection, the variability in long-term outcomes highlights the critical importance of preoperative tumor characteristics and treatment response assessment. Optimizing patient selection and enhancing postoperative surveillance and intervention strategies may improve long-term outcomes for these patients.

In conclusion, CCL11 over-production drives HSC activation, creating an ECM-disorganized and immunosuppressive TME via the CCL11/CCR3 axis in LEN-treated HCC. Combination therapy with CCR3 inhibitor and LEN might represent a novel therapeutic strategy.

UFMylation is a critical posttranslational modification that destabilizes SREBP1, and its dysregulation contributes to HCC progression. Targeting the UFMylation-SREBP1 axis, particularly through Fatostatin and Lenvatinib combination therapy, represents a novel therapeutic strategy for HCC.

Moreover, CRP responder and CRP flare-responder status were independent risk factors for OS (p < 0.001) and PFS (p < 0.001). CRP kinetics may have predictive value for prognosis in HCC patients undergoing TACE-LEN-ICIs.

P3, N=863, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jan 2027 --> Jun 2026

This study validates VETC-positive HCC as a distinct entity with a high risk of postoperative recurrence and validates the combination of PD-1 inhibitors with Lenvatinib as its preferred therapeutic strategy.

P2, N=51, Active, not recruiting, Institut Curie | Trial primary completion date: May 2025 --> Oct 2026